Aion Therapeutic Inc. has filed several plant-based patents with the USPTO.
Aion Therapeutic Inc. has filed several plant-based patents with the USPTO.
Numinus seeks to raise CAD$4.0 million at an offering price of CAD$0.25 per unit.
Calgary-based Magic Med Industries has raised CAD$1,642,880 from the sale of 6,571,520 shares.
A new functional-and-psychedelic mushroom company is preparing to go public.
A major IPO can be expected to attract a lot of new attention (and capital) to the psychedelic drug industry.
Novamind Ventures' new CMO has led over 100 clinical trials and currently serves as a Coordinating Investigator for MAPS.
Champignon Brands advises that the BCSC has revoked its original cease trade order (June 19, 2020), but a replacement order remains in effect.
As the Renaissance for psychedelic drugs progresses, we see these substances acquiring mainstream status in various ways.
Certain large Mydecine shareholders have entered into a voluntary lock-up, covering 52,908,420 common shares.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now